tiprankstipranks
Analyst Profile
Followed by 403 other investors
.
Yigal Nochomovitz

Yigal Nochomovitz

Citigroup
Wall Street Analyst
Ranked #949 out of 8,014 Analysts on TipRanks (#1,670 out of 21,455 overall experts)

Success Rate

47%
153 out of 327 Profitable Transactions

Average Return

8.80%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Yigal Nochomovitz's ratings since 2014 and opened each position for the duration of 1 Year:
46.79% of your transactions would have been profitable with an average return of 8.8%

Stock Rating Distribution

453Ratings
75.06% Buy
20.75% Hold
4.19% Sell
Distribution of Yigal Nochomovitz's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Mirati Therapeutics
(MRTX)
Rating Type:Buy
Dates:Sep 19, 2017 - Sep 19, 2018
Gain:445.70%
The most profitable rating made by Yigal Nochomovitz

Yigal Nochomovitz's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
ImmunoGen
Hold
Assigned
100%
+0.90%
3
Kamada
Hold
Assigned
0.00%
3
SELLAS Life Sciences Group
Hold
Assigned
0.00%
3
Merrimack Pharmaceuticals
Buy
Assigned
$11.00
(155.22% Upside)
67%
+1.80%
5
Caladrius Biosciences
Buy
Initiated
$10.00
(1762.55% Upside)
0%
-86.50%
1
TRACON Pharmaceuticals
Buy
Reiterated
$26.00
(1150.00% Upside)
0%
-56.45%
2
Karyopharm Therapeutics
Buy
Reiterated
$53.00
(955.78% Upside)
0%
-67.33%
5
Ocular Therapeutix
Buy
Reiterated
$49.00
(797.44% Upside)
0%
-69.80%
6
Enlivex Therapeutics
Buy
Reiterated
$32.00
(527.45% Upside)
0%
-36.38%
6
Verastem
Hold
Assigned
0.00%
2
List of latest recommendations made by Yigal Nochomovitz. Click to expand and see Yigal Nochomovitz's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More